BusinessAkari Therapeutics Demonstrates Positive Response with Coversin in Ongoing Phase 2 PNH Trial and in Additional Clinical TargetsBy Nasdaq OMXApr 24, 2017, 11:15 AM UTC
BusinessAkari Therapeutics Announces R&D Day on April 24, 2017By Nasdaq OMXMar 17, 2017, 11:00 AM UTC
BusinessAkari Therapeutics Expands Clinical and Regulatory Teams with Industry VeteransBy Nasdaq OMXJan 4, 2017, 12:00 PM UTC
BusinessAkari Therapeutics Announces Corporate Update with New Positive Clinical Data and a New Pipeline of Tick Derived and Engineered ProteinsBy Nasdaq OMXDec 5, 2016, 12:00 PM UTC
BusinessAkari Therapeutics to Attend Upcoming Investor Conferences In NovemberBy Nasdaq OMXNov 11, 2016, 12:00 PM UTC
BusinessAkari Therapeutics to Present at Upcoming Investor Conferences on September 27 and 28 in New York CityBy Nasdaq OMXSep 16, 2016, 4:18 PM UTC
BusinessAkari Therapeutics Announces Receipt of Orphan Drug Designation for Coversin from the U.S. FDA for Treatment of Paroxysmal Nocturnal HemoglobinuriaBy Nasdaq OMXSep 12, 2016, 11:15 AM UTC
BusinessAkari Therapeutics Plc and XL-protein GmbH Sign License Agreement to Develop a Long Acting Version of Coversin Using PASylation® TechnologyBy Nasdaq OMXApr 14, 2016, 11:30 AM UTC
